Gerdemann et al. reported on an important technical advance in the ability to generate tumor-specific T cells. T cells are activated in the presence of autologous dendritic cells (DCs) transfected with plasmids encod-ing multiple potential tumor-associated antigens or pulsed with tumor-associated antigen peptides. This permits generation of T cells specific for multiple antigens and multiple epitopes. Antigens and epitopes would not be restricted to a specific HLA polymorphism as occurs when tumor-specific T cells are generated against only 1 specific peptide that is expressed in an HLA-restricted manner. Polyclonal T cell activation occurs by exposure to a potent cocktail of cytokines developed to promote generation of Th1 cells (IL12), inhibit expansion of Tregs (IL-6) and provide enhanced survival and proliferative signals (IL15). To target lymphoma, they combined three potential lymphoma associated antigens, SSX2, Survivin, and MAGEA4 and generated ''multi-tumor associated antigen cytotoxic T cells'' (multiTAA CTL) against all three antigens from six healthy donors. They showed that these cells had activity against autologous antigen pulsed targets and whole antigen expressing fibroblasts and were not reactive against control targets. Similarly to target myeloid leukemia they combined WT1, Prame, PR3, and Survivin and generated multispecific T cells against all antigens from two healthy donors.